Open AccessAmp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real‐world analysis
Author(s) -
Wang Yutong,
Bao Li,
Chu Bin,
Chen Xiaohuan,
Lu Minqiu,
Shi Lei,
Gao Shan,
Fang Lijuan,
Xiang Qiuqing,
Ding Yuehua
Publication year - 2022
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24375
Subject(s) - multivariate analysis , fluorescence in situ hybridization , multiple myeloma , medicine , bone marrow , weight gain , oncology , biology , gene , chromosome , genetics , body weight
Abstract Introduction The gain/amplification (amp) of 1q21 is one of the most common high‐risk chromosome abnormality (HRCA) in multiple myeloma (MM). The prognostic value of 1q21+ remains to be controversial on the status of gain or amp and the combination of other HRCAs. Methods In this retrospective study, we included 318 newly diagnosed MM (NDMM) patients who had fluorescence in situ hybridization (FISH) data and treated with novel agents in our department. Results Our study noted MM patients with amp 1q21 were more likely accompanied with t(4;14), t(14;16), and t(14;20). Patients with amp 1q21 presented with elder age, advanced Revised International Staging System (R‐ISS) stages, anemia, and more plasma cells in bone marrow compared to patients with gain 1q21 alone and no 1q21+. Moreover, amp 1q21 alone correlated with shorter progression‐free survival (PFS) (22.8m vs. 40.5m vs. 39.6m) and overall survival (OS) (45.2m vs. NA vs. 83.5m) compared with gain 1q21 alone and no FISH abnormalities. Although the high ratio of proteasome inhibitor and immunomodulatory drugs used in patients with amp 1q21, the overall response (ORR) was the lowest compared with no 1q21+ and gain 1q21. Multivariate analysis defined amp 1q21 as an independent prognostic marker for NDMM patients, rather than gain 1q21. Conclusion The amp 1q21 predict inferior treatment response and survival, especially coexisted with high‐risk IgH translocation.